Glycobiology of Viruses

Geyer, Hildegard; Geyer, Rudolf; Ernst, Beat; Hart, Gerald W.; Sînaÿ, Pierre

doi:10.1002/9783527618255.ch89

Cited by 8 publications

(3 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Olaparib kann als Monotherapie oder bei Hormonrezeptor-positiven Tumoren in Kombination mit der endokrinen Therapie eingesetzt werden. Prof. Andrew Tutt, London (England), betonte, dass adjuvant verabreichtes Olaparib das Gesamtüberleben (OS) in der Studie OlympiA verbesserte 6 . Eine solche OS-Verbesserung konnte in der Studie monarchE mit der adjuvanten endokrinen Therapie plus dem CDK4/6-Inhibitor Abemaciclib noch nicht nachgewiesen, betonte er 7 .…”

Section: Adjuvantes Olaparib Bei Hohem Rezidivrisikounclassified

Frühes Mammakarzinom

Pömmerl

2023

Onkologische Welt

View full text Add to dashboard Cite

Seit dem Jahr 2022 können auch beim frühen Mammakarzinom die Immuntherapie mit Pembrolizumab und die zielgerichtete Therapie mit Olaparib eingesetzt werden. Im Gegensatz zur metastasierten Situation spielt die PD-L1-Expression bei Patient*innen mit einem frühen triple-negativen Mammakarzinom (TNBC) als Biomarker für die Immuntherapie keine Rolle. Bei Patient*innen mit einem frühen HER2-negativen (HER–) Mammakarzinom und nachgewiesener BRCA1/2-Keimbahnmutation kann Olaparib eingesetzt werden.

show abstract

Section: Adjuvantes Olaparib Bei Hohem Rezidivrisikounclassified

Frühes Mammakarzinom

Pömmerl

2023

Onkologische Welt

View full text Add to dashboard Cite

show abstract

“…These interactions induce biological events, which are involved in cell-growth and differentiation, cellproliferation, cell-adhesion, binding of pathogens, fertilization and immune responses. [1][2][3][4][5][6] The glycans assist in protein folding and transport, they are involved in pathogenic processes like chronic inflammation, 5 viral and bacterial infections, [7][8][9][10] tumor growth and metastasis 11,12 and auto-immune disorders. 13,14 The variety of events affected by protein glycosylation is not surprising.…”

Section: Introductionmentioning

confidence: 99%

Synthetic vaccines based on N- and O-glycopeptides–molecular tools for immunotherapy and diagnostics

Westerlind¹,

Kunz²

2010

Carbohydrate Chemistry

View full text Add to dashboard Cite

This chapter summarizes available methods for the preparation of synthetic vaccines based on glycopeptides and recent advances in this field. It further includes results of their immunological evaluation. Syntheses of glycopeptides of defined chemical structure and conjugation of these compounds to a carrier protein or an immunostimulant are of interest for the development of new immunotherapeutics and/or antibody-based diagnostics. Since a number of years, the aberrant glycosylation of the tumorassociated mucin MUC1 forming tumor specific epitopes on the epithelial cell surface has been considered an attractive research target for the preparation of such vaccines. Examples of synthetic vaccines directed against the O-glycosylated MUC1 tandem repeats will here be given including synthetic MUC1 glycopeptides conjugated to a T-cell epitope peptide, to a carrier protein, to a lipid immunostimulant or the multimeric presentation of glycopeptides on dendrimers. Other attractive targets for immunotherapy are the viral envelope proteins HIV gp120 and HIV gp41 , which are highly glycosylated with high-mannose and complex type Nglycans. Examples will be given, which illustrate syntheses of high-mannose HIV gp120 or gp41 glycopeptides with the natural peptide backbone or with a nonnatural cyclic backbone to mimic the high-mannose cluster domain of HIV gp120. In addition the synthesis and immunological evaluation of a vaccine will be described, which contains the high-mannose cluster mimotope glycopeptide conjugated to an outer membrane protein complex (OMPC) as the carrier.

show abstract

“…various biological events such as cell adhesion, differentiation, and proliferation, [3][4][5] as well as in numerous pathological processes ranging from viral and bacterial infections [6][7][8] to cancer metastasis. 9,10 In fact, many human diseases, from autoimmune responses [11][12][13] to oncological transformations, 14,15 are associated with the alteration of cell surface glycosylation patterns.…”

mentioning

confidence: 99%

Glycopeptide and glycoprotein synthesis involving unprotected carbohydrate building blocks

Guo

Shao

2005

Medicinal Research Reviews

View full text Add to dashboard Cite

This review summarizes the chemical and chemoenzymatic synthesis of glycopeptides and glycoproteins using unprotected carbohydrates as key intermediates. The synthetic methods covered herein include the convergent synthesis of glycopeptides by chemoselective ligation of peptides and free glycans, solution- and solid-phase synthesis of glycopeptides by sequential peptide elongation with unprotected glycosyl amino acids or short glycopeptides as building blocks, and the synthesis of glycopeptides by enzymatic and/or chemical elongation of the free glycans. The use of unprotected carbohydrates in these syntheses can circumvent the final-stage carbohydrate deprotection, lead to highly convergent synthetic designs, and more significantly, take advantage of the commercially available free glycans isolated from nature, which could considerably facilitate the synthesis of complex glycopeptides and glycoproteins.

show abstract

Glycobiology of Viruses

Cited by 8 publications

References 59 publications

Frühes Mammakarzinom

Frühes Mammakarzinom

Synthetic vaccines based on N- and O-glycopeptides–molecular tools for immunotherapy and diagnostics

Glycopeptide and glycoprotein synthesis involving unprotected carbohydrate building blocks

Contact Info

Product

Resources

About